ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
ObsEva SA (NASDAQ: OBSV), a biopharmaceutical company focused on women’s reproductive health, will participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 8:40 AM ET. The management will engage in a fireside chat and one-on-one investor meetings. Interested parties can access the presentation via a live webcast.
ObsEva is developing innovative therapies aimed at conditions such as endometriosis, uterine fibroids, and preterm labor, enhancing women's health outcomes.
- None.
- None.
Insights
Analyzing...
Geneva, Switzerland and Boston, MA – February 17, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will be participating in a fireside chat and one-on-one investor meetings at the SVB Leerink 10th Annual Global Healthcare Conference.
Details on the presentation can be found below.
Date: Wednesday, February 24, 2021
Time:8:40 AM ET
Webcast:Click Here
The presentation and archived webcast will also be accessible under “Events Calendar” in the investors section of ObsEva’s website.
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
For further information, please contact:
CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact
Joyce Allaire 
jallaire@lifesciadvisors.com
+1 (617)-435-6602
Attachment
 
             
             
             
             
             
             
             
             
         
         
         
        